Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Senomys(SNMX)- A Taste for Success!!! -- Ignore unavailable to you. Want to Upgrade?

To: gfp927z who wrote (72)	5/3/2005 3:56:37 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 192

gfp, Couldn't agree more...biotech investing is fraught with hurdles in making it a winner. Takes only one death in phase testing or serious adverse side-effect to kill a drug..What I find amazing is the mentality that comes to play in this field..often I think it is the Mensa crowd that invests because of the intellectual discourse opportunities, totally ignoring the mundane medical stocks surrounding this field. One of my current investments is (CMN)..started buying around $15.00 and got a 3:2 stock split since..company is in medical arena in two major segments...with a kicker being a water play. And no interest here on SI because of its non-glamour image. Just to prove my thoughts I started a thread here on SI for another of my holdings. I started buying in the mid-$8.00 range. Anyway, I've never mentioned this thread anywhere on SI before now and the stock has appreciated over 20% since I first started the thread...again, a mundane stock with huge potential IMO. And again...not one poster has posted on the site, nor book marked it. It just happens to be in a non-glamour area! SNMX is a stock that also travels under the radar!

To: gfp927z who wrote (72)	5/3/2005 6:43:46 PM
From: im a survivor	Respond to of 192

EXCELLENT POST!!!!!!

To: gfp927z who wrote (72)	5/15/2005 1:58:44 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 192

Front page article in today's New York Times..."Low Carbs? Who Cares? Sugar is Latest Supermarket Demon." The article doesn't mention SNMX however it speaks directly to the issues that they are trying to address. The article is fairly balanced and points out some of the safety issues that "might" apply to sugar substitute. Some of the more salient points in the article are: "Propelled in part by the popularity of the sugar substitutes sucralose, or Splenda, the food industry last year introduced 2,225 sugarless or sugar-reduced products in the US." "Sales of reduced-sugar products in 2001, 2002, 2003, 2004 totaled about 300 million each year, however, one year period ending in the third week of April 2005 this has jumped to over $1.0 billion in sales." " Eager to meet this growing demand, food companies are working furiously to devise even better ways of replicating the taste and function of sugar in food. All current sugar substitutes have aftertaste and other flaws that distinguish them from sugar, food scientist say. Many food specialists attribute Splenda's run-away success to its sugar-like taste, but they say that it, too, falls short."